Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa neoadjuvant therapy in EGFR-mutated NSCLC
NCT00986284Phase 2Suspended
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2009
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Sep 2009; status: suspended.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00986284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00986284.